troglitazone has been researched along with Colitis in 7 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Colitis: Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Female CD-1 (ICR) mice were given a single intraperitoneal administration of AOM (10 mg/kg body weight) and followed by one-week oral exposure of 2% (w/v) DSS in drinking water, and then maintained on the basal diets mixed with or without nimesulide (0." | 3.73 | Suppression of colitis-related mouse colon carcinogenesis by a COX-2 inhibitor and PPAR ligands. ( Kohno, H; Sugie, S; Suzuki, R; Tanaka, T, 2005) |
| "Treatment with troglitazone increased apoptosis and decreased polyamine content and ornithine decarboxylase (ODC) activity in the colonic mucosa of rats treated with AOM." | 1.31 | Troglitazone, a ligand for peroxisome proliferator-activated receptor gamma, inhibits chemically-induced aberrant crypt foci in rats. ( Hosokawa, M; Kohno, H; Okumura, A; Takashima, S; Tanaka, T; Yamaguchi, N; Yoshitani , S, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (71.43) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Celinski, K | 2 |
| Dworzanski, T | 2 |
| Fornal, R | 2 |
| Korolczuk, A | 2 |
| Madro, A | 2 |
| Brzozowski, T | 1 |
| Slomka, M | 2 |
| Saubermann, LJ | 1 |
| Nakajima, A | 1 |
| Wada, K | 1 |
| Zhao, S | 1 |
| Terauchi, Y | 1 |
| Kadowaki, T | 1 |
| Aburatani, H | 1 |
| Matsuhashi, N | 1 |
| Nagai, R | 1 |
| Blumberg, RS | 1 |
| Kohno, H | 3 |
| Suzuki, R | 1 |
| Sugie, S | 1 |
| Tanaka, T | 3 |
| Yoshitani, S | 1 |
| Takashima, S | 2 |
| Okumura, A | 2 |
| Murakami, A | 1 |
| Hosokawa, M | 2 |
| Yoshitani , S | 1 |
| Yamaguchi, N | 1 |
| Su, CG | 1 |
| Lewis, JD | 1 |
7 other studies available for troglitazone and Colitis
| Article | Year |
|---|---|
Comparison of anti-inflammatory properties of peroxisome proliferator-activated receptor gamma agonists rosiglitazone and troglitazone in prophylactic treatment of experimental colitis.
Topics: Animals; Anti-Inflammatory Agents; Chromans; Colitis; Colon; Cytokines; Dextran Sulfate; Intestinal | 2013 |
Comparison of the anti-inflammatory and therapeutic actions of PPAR-gamma agonists rosiglitazone and troglitazone in experimental colitis.
Topics: Animals; Anti-Inflammatory Agents; Chromans; Colitis; Colon; Dextran Sulfate; Disease Models, Animal | 2012 |
Peroxisome proliferator-activated receptor gamma agonist ligands stimulate a Th2 cytokine response and prevent acute colitis.
Topics: Acute Disease; Animals; Antibody Formation; Antioxidants; Chromans; Colitis; Cytokines; Disease Mode | 2002 |
Suppression of colitis-related mouse colon carcinogenesis by a COX-2 inhibitor and PPAR ligands.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Bezafibrate; Body Weight; Chromans; Col | 2005 |
Ligands for peroxisome proliferator-activated receptors alpha and gamma inhibit chemically induced colitis and formation of aberrant crypt foci in rats.
Topics: Animals; Anticarcinogenic Agents; Azoxymethane; Bezafibrate; Cell Division; Chromans; Colitis; Colon | 2001 |
Troglitazone, a ligand for peroxisome proliferator-activated receptor gamma, inhibits chemically-induced aberrant crypt foci in rats.
Topics: Animals; Antineoplastic Agents; Apoptosis; Azoxymethane; Biogenic Polyamines; Carcinogens; Chromans; | 2001 |
Antineoplastic and anti-inflammatory effects of PPAR ligands in colitis.
Topics: Animals; Antioxidants; Bezafibrate; Chromans; Colitis; Colon; DNA-Binding Proteins; Rats; Rats, Inbr | 2001 |